- Conditions
- Breast Cancer, Breast Neoplasms
- Interventions
- Bevacizumab, Anastrozole, Fulvestrant
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 11
- States / cities
- Fort Myers, Florida • Jacksonville, Florida • Orlando, Florida + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 1,005
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Ivonescimab Injection, Pembrolizumab Injection
- Biological
- Lead sponsor
- Summit Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 780 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 97
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 86 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Ramucirumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 399 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 8
- States / cities
- Daly City, California • Los Angeles, California • Washington D.C., District of Columbia + 5 more
- Conditions
- Chronic Myelogenous Leukemia
- Interventions
- Nilotinib followed by treatment-free
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 10
- States / cities
- Fort Myers, Florida • Miami Lakes, Florida • Tampa, Florida + 7 more
- Conditions
- Renal Cell Cancer
- Interventions
- Avelumab (MSB0010718C), Axitinib (AG-013736), Sunitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 886 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 93
- States / cities
- Daphne, Alabama • Mobile, Alabama • Beverly Hills, California + 41 more
- Conditions
- Ovarian Neoplasms, Ovarian Cancer
- Interventions
- Sacituzumab tirumotecan, Bevacizumab, Rescue Medications
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Walnut Creek, California • Miami Beach, Florida + 23 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Tomivosertib, Pembrolizumab, Pemetrexed
- Drug · Biological
- Lead sponsor
- Effector Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 131
- States / cities
- Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 105 more
- Conditions
- Breast Cancer
- Interventions
- Gemcitabine, Sorafenib, Placebo, Capecitabine
- Drug
- Lead sponsor
- Accelerated Community Oncology Research Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 44
- States / cities
- Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 37 more
- Conditions
- Lung Cancer
- Interventions
- Pemetrexed, Gemcitabine
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer, Fallopian Tube Carcinoma
- Interventions
- Denileukin Diftitox/SC Pegylated IFNα-2a
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Colon Cancer, Colorectal Cancer, Rectal Cancer, Metastatic Colorectal Cancer
- Interventions
- Panitumumab, Bevacizumab, mFOLFOX6
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Berkeley, California + 59 more
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab (MK-3475), Bacillus Calmette-Guérin (BCG)
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Breast Cancer
- Interventions
- TAS-108
- Drug
- Lead sponsor
- SRI International
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer
- Interventions
- Cobimetinib, Paclitaxel, Placebo, Atezolizumab, Nab-Paclitaxel
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Miami, Florida • Orlando, Florida + 8 more
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer
- Interventions
- Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab, Chemotherapy
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 726 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 18
- States / cities
- New Haven, Connecticut • Skokie, Illinois • Kansas City, Kansas + 15 more
- Conditions
- Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
- Interventions
- IO102-IO103 in combination with pembrolizumab
- Drug
- Lead sponsor
- IO Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 9
- States / cities
- Duarte, California • Sacramento, California • San Diego, California + 6 more
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- Cvac, Placebo
- Biological
- Lead sponsor
- Prima BioMed Ltd
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Nab paclitaxel, Gemcitabine, Dociparstat
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Burbank, California • Greenbrae, California + 12 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab, Lazertinib, Chemotherapy: Pemetrexed, Chemotherapy: Carboplatin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 150
- States / cities
- Daphne, Alabama • Huntsville, Alabama • Goodyear, Arizona + 117 more
- Conditions
- Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Interventions
- Pemigatinib, Pembrolizumab, Gemcitabine, Carboplatin
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 13
- States / cities
- Greenbrae, California • Newark, Delaware • Marietta, Georgia + 10 more
- Conditions
- Atrial Fibrillation
- Interventions
- Anti Arrhythmics, Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation
- Drug · Procedure
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • The Bronx, New York • Cleveland, Ohio + 1 more
- Conditions
- Leukemia
- Interventions
- White Blood Cell Transfusion
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pembrolizumab, Favezelimab/Pembrolizumab, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Vibostolimab/Pembrolizumab
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 10
- States / cities
- San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 6 more
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma
- Interventions
- Acoustic Cluster Therapy, Modified FOLFIRINOX
- Combination Product · Drug
- Lead sponsor
- EXACT Therapeutics AS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Stanford, California • Boston, Massachusetts + 4 more